Physician profile
Patrick Cahill
NPI 1134229909
$8,107.77
in general payments reported to CMS, 2019-2025
35 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $878 · 2021: $991 · 2022: $1,406 · 2023: $1,481 · 2024: $1,146 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,831 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,830.56 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,339.71 | 2019-2024 | Lo Loestrin Fe, Orilissa, Qulipta |
| Mayne Pharma Commercial LLC | $615.92 | 2021-2025 | |
| Astellas Pharma US INC | $615.69 | 2019-2025 | Veozah |
| Avion Pharmaceuticals | $479.57 | 2019-2022 | |
| Therapeuticsmd, INC. | $417.45 | 2019-2022 | |
| Exeltis, USA INC. | $321.46 | 2019-2025 | Slynd |
| Biogen, INC. | $305.47 | 2024-2025 | Zurzuvae |
| Aspira Women'S Health INC | $293.76 | 2021-2024 | Ova1 |
| Coopersurgical, INC. | $268.39 | 2019-2025 | Paragard T 380a, Paragard T 380a, Insorb |
| Sumitomo Pharma America, INC. | $225.26 | 2023-2025 | Myfembree |
| Exact Sciences Corporation | $212.43 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $206.94 | 2019-2025 | |
| Myovant Sciences INC. | $179.00 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $171.51 | 2020-2025 | |
| Evofem Biosciences, INC. | $163.97 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $118.69 | 2019-2025 | Intrarosa, Femlyv, Femring |
| Medicem INC. | $104.97 | 2020-2021 | |
| Lupin INC. | $98.30 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $86.53 | 2019-2024 | Gardasil 9, Gardasil |
| Scynexis, INC. | $85.58 | 2022 | |
| Allergan, INC. | $84.88 | 2019-2020 | |
| Agile Therapeutics, INC. | $82.01 | 2021-2022 | |
| Conmed Corporation | $77.79 | 2025 | Airseal |
| Organon LLC | $70.33 | 2022-2024 | Nexplanon |
| Shield Therapeutics INC | $64.78 | 2023-2024 | Accrufer |
| Duchesnay USA Incorporated | $63.02 | 2019 | |
| Mylan Pharmaceuticals INC. | $61.75 | 2020 | |
| Amag Pharmaceuticals, INC. | $57.64 | 2019-2020 | |
| Hologic Sales and Service, LLC | $53.31 | 2020-2025 | Aptima |
| Myriad Women'S Health, INC. | $41.23 | 2023 | |
| Alexion Pharmaceuticals, INC. | $39.40 | 2019 | |
| Vertical Pharmaceuticals, LLC | $33.92 | 2019 | |
| Mission Pharmacal Company | $32.38 | 2020 | |
| Meditrina | $18.92 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Cahill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.